Log inTry free

Caribou Biosciences (CRBU) stock

Market cap $131M

$1.14
-4.62%

After-hours. Prices 15 minutes old, as of 6:04 PM ET. Pro members see real-⁠time prices.

Quality Score
-3
Poor
In its industry
#204of 300
Biotech

CRBU's Quality Score fell 2 points on Mon, Oct 5, to -3. Its average daily range rose to 5.2%, with a $103M loss over four quarters and no positive free cash flow. 1 more reason, for Pro members.

Next2H 2026“-- CaMMouflage phase 1 initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026…”Trial data · 8-K, Jun 11
Cash$114M, about 4 quarters at the last year's spendingOn Jun 30 · the company says “into 2H 2027”

TodayCaribou Biosciences filed an 8-K reporting a change of CFO · SEC, 4:07 PM ET

Follow CRBU's trial news. Pro members can get an alert when Caribou Biosciences files news, and see its trials, share raises, and its CEO's filings.

Get an optional alert when CRBU files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Since its Nov 2021 high

Down 95%, a $66.9M loss → a $148.1M loss a year.

4 more reasons behind CRBU's -3, for Pro members

Cash$114M, about 4 quarters at the last year's spendingOn Jun 30 · the company says “into 2H 2027”

What's next for CRBU, and how long its cash lasts

From Caribou Biosciences’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.

Next step the company has named

2H 2026“-- CaMMouflage phase 1 initial dose expansion data in BCMA-naïve and BCMA-exposed patients expected in H2 2026 --”Trial data · 8-K, Jun 11

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
CaMMouflagePhase 1 · Recruiting · 50 people · main data estimated Dec 2027 · NCT05722418

For Pro members: 33 filings.

Cash runway Jun 30 balance sheet

About 4 quarters

$114M in cash and investments (the company's own count), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate is “into 2H 2027” (8-K, Mar 5).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed May 8, 2025)
  • At-the-market share sales program (S-3, filed May 8, 2025)

A shelf lets a company sell shares later; an at-the-market program sells them into the market over time. Neither is a sale by itself.

For Pro members: the amounts, and the share count against a year ago.

Insiders

Chief Technology Officer Timothy P Kelly sold 6,228 shares on Feb 25. 4 more insider trades this year.

From their own Form 4 filings: buys and sales in the market, not awards or shares withheld for tax.

Get an optional alert when Rachel Haurwitz buys or sells

For Pro members: every trade, and Rachel Haurwitz’s 10 filings and quotes.

Get an optional alert when CRBU files news on its trialSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.

DateStockDrug

8 more FDA dates and 113 trial data dates in the next 60 days. Pro members see every one, with the cash against its date and an optional alert before it. Get in free →

Why it's down

Down 38% in 3 months, 19% under its 50-day average.

Today: Caribou Biosciences filed an 8-K reporting a change of CFO (SEC, 4:07 PM ET)

Down more than its industry: the 299 other stocks in it fell a median 15% over the same 3 months.

−3Long-term trend below a falling 200-day average, down over one year, down over two years

3 more things pulling CRBU's score down, for Pro members

Why CRBU lags the market

Caribou Biosciences returned -95% over five years to the S&P 500's +91%; free cash flow went from -$33.5M to -$112.4M.

Sources: Price history, Oct 5, 2026; Annual reports, Dec 31, 2025

2 drivers and the timeline, for Pro members

Big story

Tue Oct 6: Leadership

Caribou Biosciences filed an 8-K reporting a change of CFO

From the company's 8-K filing

Get an alert on CRBU's next big story →

What's next

Expected to report Wed Nov 11, after the close

After its last 4 reports it closed -1.1% on average, higher 2 of 4 times.

What would turn CRBU's score around: 8 things, for Pro members

Alert me when CRBU's Quality Score turns up

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

  • The same page for Pro members, on AMD

    Its Quality Score and rank, the line that drives it, and the live price with the bid and ask.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on CRBU and every other stock.

  • FDA dates, counted down

    Each date in the company's own words, its cash against the date, and an optional alert before it.

  • Why a stock ranks

    Its Quality Score, its rank, and the reasons behind it, on one card.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, download a CSV, and set optional alerts.

  • Congress trades

    Each member's trades. Sort, filter, download a CSV, and set optional alerts.

  • All 14 chart checks

    Trend, volume, tight range, and buying, each lit when it fires, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports. Optional alerts before them.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    AI chips, quantum, nuclear, defense, space, and more, each stock ranked by its Quality Score.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push, email, or the bell.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name, with optional alerts.

  • A trade plan, from the chart

    Entry, stop, and two targets on every stock's page. Type your risk and it sizes the trade.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

CRBU has 1 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown
MA FAN21 EMAW.EMAHH/HL52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown
VOLVDUU/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown
ATR SQZSQUEEZENR7

The daily range is tight against its own recent history.

Buying1 of 3 shown
OBV+CLOSE HISPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on CRBU, and all 14 on every stock.Get in free →

Also on the chart

Not scored

Shown for reference. None of these counts toward the Quality Score: in our tests on 20 years of daily prices, none of them improved it.

How CRBU ranks in Biotech

CRBU is #204 of 300 by Quality Score. The top three are shown with their scores, and more by name.

More in Biotech, on the Healthcare page

When does CRBU report earnings, and what happens after?

Expected to report Wed Nov 11, after the close (in 36 days). Not yet confirmed by the company.

ReportedGapReaction5 sessions
Aug 13, 2026After close0.0%-1.9%0.0%
May 7, 2026After close+1.1%+3.2%+13.8%
Mar 5, 2026After close-2.9%+6.4%+10.5%
Nov 12, 2025After close+1.8%-12.2%-19.5%

The gap is the next open against the close before the report; the reaction is where that session closed. CRBU closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

About Caribou Biosciences

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

97 employeesBerkeley, CAcariboubio.com

Pro members see every line of every stock's score.

  • Real-⁠time prices, no delay
  • Every line of CRBU's score, with the points and the reason
  • All 14 checks on CRBU and on all 3,244 stocks
  • Every stock ranked, with the chart
  • Every filing, and optional alerts on CRBU
See all 14 checks on CRBUSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight Answers

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.

Do I need an account?

Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.